Sec. 3041. CLARIFYING FDA POSTMARKET AUTHORITIES
370 words·~2 min read·
/statute-compilations/comps-15290/sec-3041A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
## SEC. 3041 CLARIFYING FDA POSTMARKET AUTHORITIES ###
(a)Definition of Adverse Drug Experience Section 505-1(b)(1)(E) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1(b)(1)(E)) is amended by striking “of the drug” and inserting “of the drug, which may include reduced effectiveness under the conditions of use prescribed in the labeling of such drug, but which may not include reduced effectiveness that is in accordance with such labeling”. ###
(b)Safety Labeling Changes Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(o)(4)) is amended— ####
(1)in subparagraph
(A)by— #####
(A)striking “Safety information” and inserting “Safety or new effectiveness information”; and #####
(B)by striking “If the Secretary becomes” and all that follows through “in the labeling of the drug” and inserting “If the Secretary becomes aware of new information, including any new safety information or information related 132 STAT. 3943 to reduced effectiveness, that the Secretary determines should be included in the labeling of the drug”; ####
(2)in clause
(i)of subparagraph (B), by inserting before the semicolon “, or new effectiveness information”; ####
(3)in subparagraph
(C)by striking “safety information” and inserting “safety or new effectiveness information”; and ####
(4)in subparagraph
(E)by striking “safety information” and inserting “safety or new effectiveness information”. ###
(c)Guidance **[**[21 U.S.C. 355 note](/us/usc/t21/s355)**]** Not less than one year after the date of enactment of this Act, the Secretary of Health and Human Services shall issue guidance regarding the circumstances under which the Food and Drug Administration may require postmarket studies or clinical trials to assess the potential reduction in effectiveness of a drug and how such reduction in effectiveness could result in a change to the benefits of the drug and the risks to the patient. Such guidance shall also address how the Food and Drug Administration may apply this section and the amendments made thereby with respect to circumstances under which the Food and Drug Administration may require postmarket studies or clinical trials and safety labeling changes related to the use of controlled substances for acute or chronic pain. ## Subtitle B Controlled Substance Provisions ## CHAPTER 1 MORE FLEXIBILITY WITH RESPECT TO MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDERS
Connectionstraces to 2
Traces to 2 documents
Citation graph
cites case law
Cites 2Cited by 0 across 0 sources